3.9 Article

Determining If a Somatic Tumor Mutation Is Targetable and Options for Accessing Targeted Therapies

期刊

JOURNAL OF ONCOLOGY PRACTICE
卷 15, 期 11, 页码 575-+

出版社

AMER SOC CLINICAL ONCOLOGY
DOI: 10.1200/JOP.19.00262

关键词

-

类别

向作者/读者索取更多资源

Targeted cancer therapies are drugs and biologics designed to affect cancer cell growth by blocking or interfering with specific molecular pathways in the cancer cell. Use of targeted agents usually requires verification through molecular testing that the patient's tumor harbors the molecular biomarker that is the target of the drug or is predictive of treatment benefit. Genomic mutations may be clinically actionable if they are associated with response or resistance to a potential therapy. If a genomic test reveals an actionable alteration, there are several options for accessing the targeted therapy. This article is intended to help clinicians determine if a tumor mutation is potentially treatable with a marketed or investigational drug or biologic product and to offer guidance on how to access the product of interest. (C) 2019 by American Society of Clinical Oncology

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

3.9
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据